7/ Imatinib (Gleevec) for chronic myeloid leukemia. Dramatic treatment that turned around a fatal cancer. The very essence of what targeted therapy is. 1998. Brian Druker. @nytimesnytimes.com/2009/11/03/sci…
8/ The first monoclonal antibody for the treatment of cancer: Rituximab. 1997. Ron Levy, David Maloney and colleagues. pnas.org/doi/10.1073/pn…@PNASNews
9/ Immunomodulatory drugs: Taking the most scorned drug ever (thalidomide) & making it into an effective cancer treatment. 1998. Bart Barlogie.
6 of the 10 on the list cured previously incurable systemic cancer with finite duration therapy and established an aspirational vision for all cancers. Where we need to be. The others had dramatic and sustained impact on a cancer or the field overall.
They challenge us.
Great points in replies about check point inhibitors, ondansetron, allogeneic transplantation.
The reported COVID deaths underestimate global excess mortality.
The current excess mortality is mostly likely due to COVID itself, the impact COVID has had on the health of the public in the last 3 years, and the impact of COVID on healthcare delivery overall.
The reporting of COVID and COVID deaths varies across countries. In lower income countries very few COVID deaths are reported but excess mortality data tell a different story.
The revised IMWG criteria redefining myeloma and related disorders was published in 2014 in @TheLancetOncol — and is now the most cited paper in the field. thelancet.com/journals/lanon…
I just attended one of the biggest cancer meetings in the world. #ASH22@ASH_hematology
For my followers here is a snapshot of the incredible progress happening with cancer treatment. It’s good. Thread.
1/ There is a revolution in cancer therapy that uses the power of our own immune system to fight cancer cells:
CAR-T cells
Bispecific antibodies
Both these approaches have already produced spectacular results in many cancers and we are just starting.
2/ CAR-T cells: take your own immune system cells out, engineer them to target a specific cancer, and then put them back in the body to go kill the cancer cells. A few CAR-T products have already been FDA approved. Many more to come. my.clevelandclinic.org/health/treatme…
Early transplant preferred. But for selected standard risk patients depending on preference, delayed is also OK. Maintenance varies by risk stratification.
3. First relapse. The approach depends on refractoriness to Len and CD38moAB. For CD38 Moab either Daratumumab or Isatuximab are OK. Depends on cost and availability. #ASH22
At #ASH22 my colleague @myelomaMD will present the initial results of the ASCENT trial, aka the 2nd Cure trial to test the hypothesis whether myeloma can be cured if highly active combination therapy is given early at the smoldering myeloma stage. ash.confex.com/ash/2022/webpr…
Updated results from the 1st Cure trial, GEM-CESAR led by @mvmateos is also being presented at #ASH22
These trials are part of a planned series of trials investigating whether the incurability of myeloma is related to the fact that we have traditionally started effective therapy only after the disease has spread and mutated to the point where it is no longer curable.